DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+42.82%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$417M
AUM Growth
+$417M
(+30%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$6.14M |
| 2 |
Biohaven
BHVN
|
$5.73M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$3.28M |
| 5 |
Galapagos
GLPG
|
$2.85M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$7.23M |
| 3 |
Cytokinetics
CYTK
|
$6.64M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$4.75M |
| 5 |
Nurix Therapeutics
NRIX
|
$4.38M |
Sector Composition
| 1 | Healthcare | 85.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $43.2M | 10.36% | 484,000 -81,000 | -14% | -$7.23M |
|
|
2
Cytokinetics
CYTK
$4.23B
| $33.4M | 8% | 400,000 -79,538 | -17% | -$6.64M |
|
3
Stereotaxis
STXS
$261M
| $23.9M | 5.74% | 13,680,554 | – | – |
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $18.4M | 4.4% | 516,341 +16,521 | +3% | +$588K |
|
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| $16M | 3.85% | 742,574 +284,201 | +62% | +$6.14M |
|
6
Ascendis Pharma
ASND
$11.8B
| $15.6M | 3.73% | 123,472 -12,740 | -9% | -$1.6M |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $15.2M | 3.65% | 48,145 -4,728 | -9% | -$1.5M |
|
8
Revolution Medicines
RVMD
$7.1B
| $14.7M | 3.52% | 511,894 +38,500 | +8% | +$1.1M |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $13.9M | 3.34% | 102,500 | – | – |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $12.7M | 3.05% | 276,739 -3,799 | -1% | -$175K |
|
11
Merus
MRUS
$4.98B
| $12.5M | 3% | 454,870 -30,000 | -6% | -$825K |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $10.2M | 2.45% | 110,863 -138,658 | -56% | -$12.8M |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $10M | 2.4% | 686,463 +100,000 | +17% | +$1.46M |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $9.57M | 2.29% | 72,615 -1,000 | -1% | -$132K |
|
15
DexCom
DXCM
$29.5B
| $8.38M | 2.01% | 67,552 | – | – |
|
16
KalVista Pharmaceuticals
KALV
$678M
| $7.36M | 1.76% | 601,032 -4,500 | -0.7% | -$55.1K |
|
|
17
Biohaven
BHVN
$1.63B
| $7.22M | 1.73% | 168,772 +133,772 | +382% | +$5.73M |
|
18
Kura Oncology
KURA
$686M
| $7.08M | 1.7% | 492,684 -58,100 | -11% | -$835K |
|
|
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.69M | 1.6% | 231,748 | – | – |
|
20
Tandem Diabetes Care
TNDM
$845M
| $6.53M | 1.56% | 220,708 | – | – |
|
21
Axogen
AXGN
$743M
| $6.39M | 1.53% | 935,894 | – | – |
|
|
TSVT
22
DELISTED
2seventy bio
TSVT
| $6.18M | 1.48% | 1,447,465 | – | – |
|
|
IMGN
23
DELISTED
Immunogen Inc
IMGN
| $5.74M | 1.38% | 193,661 +110,661 | +133% | +$3.28M |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $5.31M | 1.27% | +245,000 | New | +$5.31M |
|
|
25
Galapagos
GLPG
$2.07B
| $5.29M | 1.27% | 130,175 +70,000 | +116% | +$2.85M |
|